25 XP   0   0   10

Jasper Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Jasper Therapeutics Inc together

PenkeI guess you are interested in Jasper Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Jasper Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Jasper Therapeutics Inc

I send you an email if I find something interesting about Jasper Therapeutics Inc.

Quick analysis of Jasper Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Jasper Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$5.36
Expected worth in 1 year
$9.73
How sure are you?
31.3%

+ What do you gain per year?

Total Gains per Share
$4.38
Return On Investment
20.3%

For what price can you sell your share?

Current Price per Share
$21.59
Expected price per share
$15.50 - $31.40
How sure are you?
50%

1. Valuation of Jasper Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$21.59

Intrinsic Value Per Share

$-56.55 - $-67.46

Total Value Per Share

$-51.19 - $-62.11

2. Growth of Jasper Therapeutics Inc (5 min.)




Is Jasper Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$80.7m$52.6m$49.9m48.7%

How much money is Jasper Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$16.5m-$5.9m-$10.5m-63.8%
Net Profit Margin838.8%19.8%--

How much money comes from the company's main activities?

3. Financial Health of Jasper Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#419 / 1016

Most Revenue
#513 / 1016

Most Profit
#652 / 1016

Most Efficient
#18 / 1016

What can you expect buying and holding a share of Jasper Therapeutics Inc? (5 min.)

Welcome investor! Jasper Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Jasper Therapeutics Inc.

What can you expect buying and holding a share of Jasper Therapeutics Inc?

First you should know what it really means to hold a share of Jasper Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Jasper Therapeutics Inc is $21.59. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Jasper Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Jasper Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.36. Based on the TTM, the Book Value Change Per Share is $1.09 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.91 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Jasper Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.10-5.1%-0.39-1.8%-0.26-1.2%-0.31-1.4%-0.31-1.4%
Usd Book Value Change Per Share4.5020.8%1.095.1%-0.91-4.2%0.331.6%0.331.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share4.5020.8%1.095.1%-0.91-4.2%0.331.6%0.331.6%
Usd Price Per Share0.79-1.17-1.69-5.57-5.57-
Price to Earnings Ratio-0.18--1.60--4.31-16.42-16.42-
Price-to-Total Gains Ratio0.18--0.91--3.18--47.94--47.94-
Price to Book Ratio0.15-0.90-1.05-1.00-1.00-
Price-to-Total Gains Ratio0.18--0.91--3.18--47.94--47.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share21.59
Number of shares46
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share1.090.33
Usd Total Gains Per Share1.090.33
Gains per Quarter (46 shares)50.3215.40
Gains per Year (46 shares)201.2861.61
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1020119106252
204033920123114
306045930185176
408057940246238
5010069950308300
60120811960370362
70140913970431424
80161015980493486
90181117990554548
100201320000616610

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%2.014.00.012.5%2.014.00.012.5%2.014.00.012.5%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%5.011.00.031.3%5.011.00.031.3%5.011.00.031.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.016.00.0%0.00.016.00.0%0.00.016.00.0%
Total Gains per Share2.02.00.050.0%4.08.00.033.3%5.011.00.031.3%5.011.00.031.3%5.011.00.031.3%

Fundamentals of Jasper Therapeutics Inc

About Jasper Therapeutics Inc

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.

Fundamental data was last updated by Penke on 2024-03-31 11:03:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Jasper Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Jasper Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -808.0% means that $-8.08 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Jasper Therapeutics Inc:

  • The MRQ is -808.0%. The company is making a huge loss. -2
  • The TTM is 838.8%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ-808.0%TTM838.8%-1,646.8%
TTM838.8%YOY19.8%+819.0%
TTM838.8%5Y236.1%+602.7%
5Y236.1%10Y236.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-808.0%-199.6%-608.4%
TTM838.8%-213.0%+1,051.8%
YOY19.8%-279.3%+299.1%
5Y236.1%-438.4%+674.5%
10Y236.1%-605.5%+841.6%
1.1.2. Return on Assets

Shows how efficient Jasper Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • -17.4% Return on Assets means that Jasper Therapeutics Inc generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Jasper Therapeutics Inc:

  • The MRQ is -17.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.4%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.4%TTM-14.4%-3.0%
TTM-14.4%YOY-11.6%-2.8%
TTM-14.4%5Y-11.8%-2.6%
5Y-11.8%10Y-11.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.4%-13.5%-3.9%
TTM-14.4%-12.9%-1.5%
YOY-11.6%-11.8%+0.2%
5Y-11.8%-14.1%+2.3%
10Y-11.8%-16.0%+4.2%
1.1.3. Return on Equity

Shows how efficient Jasper Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • -21.1% Return on Equity means Jasper Therapeutics Inc generated $-0.21 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Jasper Therapeutics Inc:

  • The MRQ is -21.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-21.1%TTM-16.8%-4.4%
TTM-16.8%YOY-15.1%-1.6%
TTM-16.8%5Y-45.6%+28.8%
5Y-45.6%10Y-45.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-21.1%-16.9%-4.2%
TTM-16.8%-16.1%-0.7%
YOY-15.1%-15.1%0.0%
5Y-45.6%-19.9%-25.7%
10Y-45.6%-20.9%-24.7%

1.2. Operating Efficiency of Jasper Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Jasper Therapeutics Inc is operating .

  • Measures how much profit Jasper Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -863.8% means the company generated $-8.64  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Jasper Therapeutics Inc:

  • The MRQ is -863.8%. The company is operating very inefficient. -2
  • The TTM is 636.9%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ-863.8%TTM636.9%-1,500.7%
TTM636.9%YOY-30.2%+667.1%
TTM636.9%5Y192.8%+444.1%
5Y192.8%10Y192.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-863.8%-295.1%-568.7%
TTM636.9%-225.8%+862.7%
YOY-30.2%-288.4%+258.2%
5Y192.8%-477.4%+670.2%
10Y192.8%-625.6%+818.4%
1.2.2. Operating Ratio

Measures how efficient Jasper Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 8.64 means that the operating costs are $8.64 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Jasper Therapeutics Inc:

  • The MRQ is 8.638. The company is inefficient in keeping operating costs low. -1
  • The TTM is -6.673.
Trends
Current periodCompared to+/- 
MRQ8.638TTM-6.673+15.311
TTM-6.673YOY0.302-6.975
TTM-6.6735Y-1.843-4.831
5Y-1.84310Y-1.8430.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.6383.090+5.548
TTM-6.6733.264-9.937
YOY0.3023.783-3.481
5Y-1.8435.679-7.522
10Y-1.8437.894-9.737

1.3. Liquidity of Jasper Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Jasper Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.19 means the company has $7.19 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Jasper Therapeutics Inc:

  • The MRQ is 7.187. The company is very able to pay all its short-term debts. +2
  • The TTM is 11.508. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.187TTM11.508-4.320
TTM11.508YOY8.722+2.785
TTM11.5085Y8.589+2.919
5Y8.58910Y8.5890.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.1873.914+3.273
TTM11.5084.220+7.288
YOY8.7225.388+3.334
5Y8.5896.045+2.544
10Y8.5896.406+2.183
1.3.2. Quick Ratio

Measures if Jasper Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 7.04 means the company can pay off $7.04 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Jasper Therapeutics Inc:

  • The MRQ is 7.042. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 11.290. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.042TTM11.290-4.248
TTM11.290YOY8.391+2.899
TTM11.2905Y8.182+3.108
5Y8.18210Y8.1820.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0423.572+3.470
TTM11.2903.998+7.292
YOY8.3915.390+3.001
5Y8.1825.969+2.213
10Y8.1826.287+1.895

1.4. Solvency of Jasper Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Jasper Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Jasper Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.15 means that Jasper Therapeutics Inc assets are financed with 15.4% credit (debt) and the remaining percentage (100% - 15.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Jasper Therapeutics Inc:

  • The MRQ is 0.154. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.128. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.154TTM0.128+0.026
TTM0.128YOY0.193-0.065
TTM0.1285Y0.292-0.164
5Y0.29210Y0.2920.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1540.336-0.182
TTM0.1280.334-0.206
YOY0.1930.269-0.076
5Y0.2920.366-0.074
10Y0.2920.390-0.098
1.4.2. Debt to Equity Ratio

Measures if Jasper Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.7% means that company has $0.19 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Jasper Therapeutics Inc:

  • The MRQ is 0.187. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.149. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.187TTM0.149+0.038
TTM0.149YOY0.242-0.093
TTM0.1495Y0.597-0.448
5Y0.59710Y0.5970.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1870.382-0.195
TTM0.1490.396-0.247
YOY0.2420.335-0.093
5Y0.5970.434+0.163
10Y0.5970.465+0.132

2. Market Valuation of Jasper Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Jasper Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Jasper Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -0.18 means the investor is paying $-0.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Jasper Therapeutics Inc:

  • The EOD is -4.904. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.179. Based on the earnings, the company is expensive. -2
  • The TTM is -1.599. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.904MRQ-0.179-4.724
MRQ-0.179TTM-1.599+1.420
TTM-1.599YOY-4.308+2.709
TTM-1.5995Y16.419-18.018
5Y16.41910Y16.4190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.904-2.259-2.645
MRQ-0.179-2.569+2.390
TTM-1.599-2.664+1.065
YOY-4.308-4.120-0.188
5Y16.419-6.258+22.677
10Y16.419-6.171+22.590
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Jasper Therapeutics Inc:

  • The EOD is -4.866. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -0.178. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.112. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.866MRQ-0.178-4.688
MRQ-0.178TTM-2.112+1.934
TTM-2.112YOY-1.293-0.819
TTM-2.1125Y-13.106+10.995
5Y-13.10610Y-13.1060.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.866-2.924-1.942
MRQ-0.178-3.246+3.068
TTM-2.112-3.488+1.376
YOY-1.293-5.620+4.327
5Y-13.106-8.315-4.791
10Y-13.106-8.826-4.280
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Jasper Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.15 means the investor is paying $0.15 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Jasper Therapeutics Inc:

  • The EOD is 4.030. Based on the equity, the company is fair priced.
  • The MRQ is 0.147. Based on the equity, the company is cheap. +2
  • The TTM is 0.899. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.030MRQ0.147+3.883
MRQ0.147TTM0.899-0.752
TTM0.899YOY1.047-0.148
TTM0.8995Y1.005-0.106
5Y1.00510Y1.0050.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.0301.851+2.179
MRQ0.1472.090-1.943
TTM0.8992.095-1.196
YOY1.0472.844-1.797
5Y1.0053.466-2.461
10Y1.0053.815-2.810
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Jasper Therapeutics Inc.

3.1. Institutions holding Jasper Therapeutics Inc

Institutions are holding 55.969% of the shares of Jasper Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-09-30Velan Capital Investment Management LP7.45086.11891121903600
2023-09-30Bvf Inc6.57480.1869990000000
2023-09-30The Carlyle Group Inc5.81890.2626876189100
2023-09-30Qiming U.S. Ventures Management, LLC5.65817.9179851964800
2023-09-30Soleus Capital Management, L.P.5.51280.536183009805250006.7516
2023-09-30Sphera Funds Management Ltd.3.77690.72515687134141312633.0633
2023-09-30Octagon Capital Advisors LP2.96740.4805446811400
2023-09-30Vanguard Group Inc2.5190.000137929581046002.836
2023-09-30Bank of America Corp2.11210.0003318030192820541.2152
2023-09-30Ally Bridge Group (NY) LLC2.08812.5833314416462693224.9056
2023-09-30Kingdon Capital Management LLC2.01890.2451304000000
2023-09-30Woodline Partners LP1.99240.0246300000000
2023-09-30Nantahala Capital Management, LLC1.59580.14372402904-74976-3.0258
2023-09-30Saturn V Capital Management LLC0.92110.4064138701513870150
2023-09-30BlackRock Inc0.877201320784-11563-0.8679
2023-09-30Geode Capital Management, LLC0.60070.0001904477-61027-6.3207
2023-09-30Morgan Stanley - Brokerage Accounts0.51860.0001780879459329142.8484
2023-09-30Mariner Wealth Advisors, LLC0.43350.0012652749-62247-8.7059
2023-09-30SCOGGIN LLC0.33740.14675080455080450
2023-12-31Fernwood Investment Management, LLC0.32850.1287494706400008.7969
Total 54.10319.908381465785+5782439+7.1%

3.2. Funds holding Jasper Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Franklin Biotechnology Discv A(acc)USD3.18760.552948017017270056.1681
2024-02-29Vanguard Total Stock Mkt Idx Inv2.65930.000640060012323344.4296
2024-02-29Franklin Biotechnology Discovery A1.60570.53442418749730067.3012
2023-12-31Forefront Tiresias Strategy0.14123.7437212777110285107.6035
2023-09-30BlackRock Extended Mkt Composite0.13650.00120568600
2023-12-31BlackRock Extended Equity Market K0.11910.001179444-361-0.2008
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.77010.002411600100
2023-12-31NT Ext Equity Mkt Idx Fd - NL0.05240.0017893400
2023-10-31Vanguard Instl Ttl Stck Mkt Idx Tr0.04970.000274930-2294143-96.8372
2023-12-31NT Ext Equity Mkt Idx Fd - L0.04570.00096876900
2023-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.04210.001633951190.1881
2024-01-31Fidelity Extended Market Index0.29250.00154406937959.423
2023-12-31Extended Equity Market Fund M0.01470.0012218810564.9972
2024-01-31Fidelity Total Market Index0.13160.000319827-1-0.005
2024-02-29Russell Inv Tax-Managed US Mid&Sm Cap S0.11950.023818001180010
2024-02-29iShares Micro-Cap ETF0.11620.04081750900
2024-01-31Fidelity Series Total Market Index0.08590.000212935-1-0.0077
2024-02-29Russell Inv US Small Cap Equity E0.07630.026811501115010
2024-01-31Fidelity Nasdaq Composite Index0.06410.0008965900
2024-02-29Vanguard Balanced Index Inv0.05780.00038701290850.1985
Total 9.7684.93462286970-1753608-76.7%

3.3. Insider Transactions

Insiders are holding 6.15% of the shares of Jasper Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-12Jeetinder Singh MahalSELL90026.44
2024-02-08Velan Capital Investment ManagBUY35000012.95
2023-11-20Thomas G WiggansBUY10006.3
2023-11-16Thomas G WiggansBUY10006
2023-10-13William LisSELL7968.5
2023-06-13Jeetinder Singh MahalSELL90016.6
2023-04-14Anna Louise FrenchSELL70014.8

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Jasper Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--4.5001.094+311%-0.908+120%0.335+1244%0.335+1244%
Book Value Per Share--5.3572.161+148%1.443+271%2.723+97%2.723+97%
Current Ratio--7.18711.508-38%8.722-18%8.589-16%8.589-16%
Debt To Asset Ratio--0.1540.128+20%0.193-20%0.292-47%0.292-47%
Debt To Equity Ratio--0.1870.149+26%0.242-23%0.597-69%0.597-69%
Dividend Per Share----0%-0%-0%-0%
Eps---1.101-0.392-64%-0.258-77%-0.312-72%-0.312-72%
Free Cash Flow Per Share---1.109-0.364-67%-0.318-71%-0.308-72%-0.308-72%
Free Cash Flow To Equity Per Share---1.127-0.082-93%-0.318-72%0.239-572%0.239-572%
Gross Profit Margin--1.0171.004+1%1.000+2%1.001+2%1.001+2%
Intrinsic Value_10Y_max---67.463--------
Intrinsic Value_10Y_min---56.549--------
Intrinsic Value_1Y_max---2.293--------
Intrinsic Value_1Y_min---2.249--------
Intrinsic Value_3Y_max---10.294--------
Intrinsic Value_3Y_min---9.758--------
Intrinsic Value_5Y_max---22.399--------
Intrinsic Value_5Y_min---20.497--------
Market Cap325229601.000+96%11885417.10099470225.303-88%61425241.261-81%169877803.156-93%169877803.156-93%
Net Profit Margin---8.0808.388-196%0.198-4185%2.361-442%2.361-442%
Operating Margin---8.6386.369-236%-0.302-97%1.928-548%1.928-548%
Operating Ratio--8.638-6.673+177%0.302+2758%-1.843+121%-1.843+121%
Pb Ratio4.030+96%0.1470.899-84%1.047-86%1.005-85%1.005-85%
Pe Ratio-4.904-2636%-0.179-1.599+792%-4.308+2304%16.419-101%16.419-101%
Price Per Share21.590+96%0.7891.167-32%1.688-53%5.566-86%5.566-86%
Price To Free Cash Flow Ratio-4.866-2636%-0.178-2.112+1087%-1.293+627%-13.106+7270%-13.106+7270%
Price To Total Gains Ratio4.798+96%0.175-0.915+622%-3.181+1914%-47.940+27439%-47.940+27439%
Quick Ratio--7.04211.290-38%8.391-16%8.182-14%8.182-14%
Return On Assets---0.174-0.144-17%-0.116-33%-0.118-32%-0.118-32%
Return On Equity---0.211-0.168-21%-0.151-28%-0.456+116%-0.456+116%
Total Gains Per Share--4.5001.094+311%-0.908+120%0.335+1244%0.335+1244%
Usd Book Value--80704000.000102560000.000-21%52610000.000+53%75211185.625+7%75211185.625+7%
Usd Book Value Change Per Share--4.5001.094+311%-0.908+120%0.335+1244%0.335+1244%
Usd Book Value Per Share--5.3572.161+148%1.443+271%2.723+97%2.723+97%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---1.101-0.392-64%-0.258-77%-0.312-72%-0.312-72%
Usd Free Cash Flow---16709000.000-13083500.000-22%-11608500.000-31%-8986413.938-46%-8986413.938-46%
Usd Free Cash Flow Per Share---1.109-0.364-67%-0.318-71%-0.308-72%-0.308-72%
Usd Free Cash Flow To Equity Per Share---1.127-0.082-93%-0.318-72%0.239-572%0.239-572%
Usd Market Cap325229601.000+96%11885417.10099470225.303-88%61425241.261-81%169877803.156-93%169877803.156-93%
Usd Price Per Share21.590+96%0.7891.167-32%1.688-53%5.566-86%5.566-86%
Usd Profit---16581000.000-16529250.0000%-5976500.000-64%-8857200.000-47%-8857200.000-47%
Usd Revenue--2052000.000871500.000+135%2642750.000-22%1265812.500+62%1265812.500+62%
Usd Total Gains Per Share--4.5001.094+311%-0.908+120%0.335+1244%0.335+1244%
 EOD+6 -2MRQTTM+11 -23YOY+13 -215Y+16 -1810Y+16 -18

4.2. Fundamental Score

Let's check the fundamental score of Jasper Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.904
Price to Book Ratio (EOD)Between0-14.030
Net Profit Margin (MRQ)Greater than0-8.080
Operating Margin (MRQ)Greater than0-8.638
Quick Ratio (MRQ)Greater than17.042
Current Ratio (MRQ)Greater than17.187
Debt to Asset Ratio (MRQ)Less than10.154
Debt to Equity Ratio (MRQ)Less than10.187
Return on Equity (MRQ)Greater than0.15-0.211
Return on Assets (MRQ)Greater than0.05-0.174
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Jasper Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.485
Ma 20Greater thanMa 5027.253
Ma 50Greater thanMa 10024.353
Ma 100Greater thanMa 20016.215
OpenGreater thanClose23.070
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Gross Profit  -367-6-373-4-377101-2762,0451,769



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets95,380
Total Liabilities14,676
Total Stockholder Equity78,440
 As reported
Total Liabilities 14,676
Total Stockholder Equity+ 78,440
Total Assets = 95,380

Assets

Total Assets95,380
Total Current Assets88,938
Long-term Assets6,442
Total Current Assets
Cash And Cash Equivalents 86,887
Net Receivables 250
Other Current Assets 1,801
Total Current Assets  (as reported)88,938
Total Current Assets  (calculated)88,938
+/-0
Long-term Assets
Property Plant Equipment 4,194
Long-term Assets Other 1,343
Long-term Assets  (as reported)6,442
Long-term Assets  (calculated)5,537
+/- 905

Liabilities & Shareholders' Equity

Total Current Liabilities12,374
Long-term Liabilities2,302
Total Stockholder Equity78,440
Total Current Liabilities
Short-term Debt 972
Accounts payable 4,149
Other Current Liabilities 7,253
Total Current Liabilities  (as reported)12,374
Total Current Liabilities  (calculated)12,374
+/-0
Long-term Liabilities
Capital Lease Obligations 2,786
Long-term Liabilities  (as reported)2,302
Long-term Liabilities  (calculated)2,786
+/- 484
Total Stockholder Equity
Common Stock1
Retained Earnings -169,600
Other Stockholders Equity 248,039
Total Stockholder Equity (as reported)78,440
Total Stockholder Equity (calculated)78,440
+/-0
Other
Capital Stock1
Cash and Short Term Investments 86,887
Common Stock Shares Outstanding 11,045
Liabilities and Stockholders Equity 95,380
Net Debt -84,101
Net Invested Capital 78,440
Net Working Capital 76,564
Property Plant and Equipment Gross 6,654
Short Long Term Debt Total 2,786



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-31
> Total Assets 
100,155
101,694
101,597
101,318
23,357
100,960
100,549
107,213
93,654
80,548
70,366
59,110
48,361
138,757
124,170
110,405
95,380
95,380110,405124,170138,75748,36159,11070,36680,54893,654107,213100,549100,96023,357101,318101,597101,694100,155
   > Total Current Assets 
100,155
1,539
1,181
964
20,685
757
423
102,407
87,831
73,799
63,286
52,411
41,731
132,508
118,567
105,218
88,938
88,938105,218118,567132,50841,73152,41163,28673,79987,831102,40742375720,6859641,1811,539100,155
       Cash And Cash Equivalents 
1,213
1,213
914
758
19,838
591
310
100,905
84,701
70,400
60,814
50,950
38,250
129,400
115,812
103,867
86,887
86,887103,867115,812129,40038,25050,95060,81470,40084,701100,90531059119,8387589141,2131,213
       Short-term Investments 
100,155
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000100,155
       Net Receivables 
0
0
0
0
600
298
298
298
698
563
443
384
663
250
330
268
250
2502683302506633844435636982982982986000000
       Inventory 
0
0
0
0
0
0
0
1,194
-698
2,809
2,002
-384
0
1,867
1,772
672
0
06721,7721,8670-3842,0022,809-6981,1940000000
   > Long-term Assets 
100,155
100,155
100,416
100,355
2,672
100,204
100,126
4,806
5,823
6,749
7,080
6,699
6,630
6,249
5,603
5,187
6,442
6,4425,1875,6036,2496,6306,6997,0806,7495,8234,806100,126100,2042,672100,355100,416100,155100,155
       Property Plant Equipment 
0
0
0
0
2,029
3,646
4,047
4,461
4,833
5,721
6,086
5,739
5,454
5,107
4,741
4,359
4,194
4,1944,3594,7415,1075,4545,7396,0865,7214,8334,4614,0473,6462,0290000
       Long Term Investments 
100,155
100,403
100,416
100,355
0
100,204
100,126
0
0
0
0
0
0
0
0
0
0
0000000000100,126100,2040100,355100,416100,403100,155
       Other Assets 
0
0
0
0
0
631
4,071
345
990
1,028
994
960
0
0
0
0
0
000009609941,0289903454,07163100000
> Total Liabilities 
3,611
3,611
3,758
3,680
58,487
11,101
14,259
28,611
24,136
12,443
11,585
11,545
12,372
13,559
13,965
16,272
14,676
14,67616,27213,96513,55912,37211,54511,58512,44324,13628,61114,25911,10158,4873,6803,7583,6113,611
   > Total Current Liabilities 
111
111
258
180
4,012
181
329
9,159
8,020
5,969
6,622
7,421
7,065
7,892
8,972
11,906
12,374
12,37411,9068,9727,8927,0657,4216,6225,9698,0209,1593291814,012180258111111
       Short-term Debt 
0
0
0
0
0
0
0
490
505
521
784
840
865
891
917
945
972
9729459178918658407845215054900000000
       Accounts payable 
111
171
258
180
1,417
181
329
2,247
3,919
1,466
2,997
3,117
1,768
3,846
1,581
3,256
4,149
4,1493,2561,5813,8461,7683,1172,9971,4663,9192,2473291811,417180258171111
       Other Current Liabilities 
0
111
258
180
2,595
181
329
870
785
3,982
2,841
3,464
4,432
3,155
389
420
7,253
7,2534203893,1554,4323,4642,8413,9827858703291812,5951802581110
   > Long-term Liabilities 
3,500
3,500
3,500
3,500
54,475
10,920
13,930
19,452
16,116
6,474
4,963
4,124
5,307
5,667
4,993
4,366
2,302
2,3024,3664,9935,6675,3074,1244,9636,47416,11619,45213,93010,92054,4753,5003,5003,5003,500
       Long term Debt Total 
0
0
0
0
0
7,420
10,430
0
0
0
0
0
0
0
0
0
0
000000000010,4307,42000000
       Warrants
93,082
93,121
92,839
92,638
0
84,860
81,290
0
0
0
0
0
0
0
0
0
0
000000000081,29084,860092,63892,83993,12193,082
       Other Liabilities 
0
0
0
0
0
851
648
16,940
13,736
3,091
1,729
1,110
2,521
0
2,676
0
0
002,67602,5211,1101,7293,09113,73616,94064885100000
> Total Stockholder Equity
5,000
5,000
5,000
5,000
-35,130
5,000
5,000
78,602
69,518
68,105
58,781
47,565
35,989
125,198
110,205
94,133
78,440
78,44094,133110,205125,19835,98947,56558,78168,10569,51878,6025,0005,000-35,1305,0005,0005,0005,000
   Common Stock
0
93,083
92,839
92,638
1
84,860
81,290
4
4
4
4
4
4
11
11
11
1
111111144444481,29084,860192,63892,83993,0830
   Retained Earnings Total Equity
2
41
-241
-442
0
-1,579
-5,149
-58,393
-67,450
-69,657
0
0
-105,135
-119,395
-135,475
0
0
00-135,475-119,395-105,13500-69,657-67,450-58,393-5,149-1,5790-442-241412
   Accumulated Other Comprehensive Income 000000000-107,2130000000
   Capital Surplus 
4,998
4,959
5,241
5,442
0
6,579
10,148
136,991
136,964
137,758
0
0
141,120
244,582
245,669
0
0
00245,669244,582141,12000137,758136,964136,99110,1486,57905,4425,2414,9594,998
   Treasury Stock00000000000000000
   Other Stockholders Equity 
0
-88,085
-87,598
-87,196
1,682
-78,281
-71,142
136,991
136,964
137,758
138,838
139,485
141,120
244,582
245,669
247,141
248,039
248,039247,141245,669244,582141,120139,485138,838137,758136,964136,991-71,142-78,2811,682-87,196-87,598-88,0850



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue-1,108
Gross Profit-1,108-1,108
 
Operating Income (+$)
Gross Profit-1,108
Operating Expense-69,381
Operating Income-70,489-70,489
 
Operating Expense (+$)
Research Development53,413
Selling General Administrative17,076
Selling And Marketing Expenses1,108
Operating Expense69,38171,597
 
Net Interest Income (+$)
Interest Income5,199
Interest Expense-0
Other Finance Cost-0
Net Interest Income5,199
 
Pretax Income (+$)
Operating Income-70,489
Net Interest Income5,199
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-66,093-74,885
EBIT - interestExpense = -70,489
-66,093
-64,465
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-70,489-66,093
Earnings Before Interest and Taxes (EBITDA)-69,381
 
After tax Income (+$)
Income Before Tax-66,093
Tax Provision-0
Net Income From Continuing Ops-64,465-66,093
Net Income-64,465
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses70,489
Total Other Income/Expenses Net4,396-5,199
 

Technical Analysis of Jasper Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Jasper Therapeutics Inc. The general trend of Jasper Therapeutics Inc is BULLISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Jasper Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (57.1%) Bearish trend (-57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Jasper Therapeutics Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 26.09 < 31.01 < 31.40.

The bearish price targets are: 21.90 > 21.19 > 15.50.

Tweet this
Jasper Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Jasper Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 11/14.
The longshort score for the Moving Averages is 8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Jasper Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Jasper Therapeutics Inc. The current macd is -0.23267893.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jasper Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Jasper Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Jasper Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Jasper Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartJasper Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Jasper Therapeutics Inc. The current adx is 29.01.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Jasper Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
Jasper Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Jasper Therapeutics Inc. The current sar is 29.52.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Jasper Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Jasper Therapeutics Inc. The current rsi is 35.49. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
Jasper Therapeutics Inc Daily Relative Strength Index (RSI) ChartJasper Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Jasper Therapeutics Inc. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Jasper Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Jasper Therapeutics Inc Daily Stochastic Oscillator ChartJasper Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Jasper Therapeutics Inc. The current cci is -200.53113095.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Jasper Therapeutics Inc Daily Commodity Channel Index (CCI) ChartJasper Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Jasper Therapeutics Inc. The current cmo is -47.88007432.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Jasper Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartJasper Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Jasper Therapeutics Inc. The current willr is -98.27400216.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Jasper Therapeutics Inc Daily Williams %R ChartJasper Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Jasper Therapeutics Inc.

Jasper Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Jasper Therapeutics Inc. The current atr is 1.9925345.

Jasper Therapeutics Inc Daily Average True Range (ATR) ChartJasper Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Jasper Therapeutics Inc. The current obv is 17,103,159.

Jasper Therapeutics Inc Daily On-Balance Volume (OBV) ChartJasper Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Jasper Therapeutics Inc. The current mfi is 32.38.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Jasper Therapeutics Inc Daily Money Flow Index (MFI) ChartJasper Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Jasper Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-16BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-18ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-19ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-22MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-07WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-04-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-08CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-04-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Jasper Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Jasper Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5035.485
Ma 20Greater thanMa 5027.253
Ma 50Greater thanMa 10024.353
Ma 100Greater thanMa 20016.215
OpenGreater thanClose23.070
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Jasper Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Jasper Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Jasper Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Jasper Therapeutics Inc

I send you an email if I find something interesting about Jasper Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Jasper Therapeutics Inc.

Receive notifications about Jasper Therapeutics Inc in your mailbox!